Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
NEXT Study: Biosimilar Filgrastim an Effective Alternative for Chemotherapy-Induced Neutropenia
By
Meg Barbor, MPH
Emerging Therapies
,
Personalized Medicine
,
Biosimilars
October 2015, Vol 6, No 9
Copenhagen, Denmark—Biosimilar filgrastim (Nivestim; Hospira), which was approved earlier this year by the European Commission but not yet by the FDA, showed effectiveness for the treatment of neutropenia and febrile neutropenia (FN) in patients undergoing cytotoxic chemotherapy for solid tumors and hematologic malignancies, according to a study presented at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology meeting.
Read Article
Atezolizumab: Another Immunotherapy for Lung Cancer?
By
Phoebe Starr
Emerging Therapies
,
Immunotherapy
,
Personalized Medicine
October 2015, Vol 6, No 9
Vienna, Austria—Immunotherapy is poised to become a game changer for patients with non–small-cell lung cancer (NSCLC).
Read Article
Immunotherapies Steal the Show at ASCO 2015
By
Chase Doyle
Immunotherapy
,
Personalized Medicine
September 2015, Vol 6, No 8
Chicago, IL—Oncologists looking to learn about immunotherapy did not have to go very far at the 2015 American Society of Clinical Oncology meeting. Many of the highest-impact presentations this year, including a plenary session, the Karnofsky Award, and the Science of Oncology Award, focused on cancer therapy’s most exciting field.
Read Article
“Designer Drug” Rociletinib Shows Encouraging Results in Patients with NSCLC and T790M Mutation
By
Alice Goodman
Emerging Therapies
,
Personalized Medicine
September 2015, Vol 6, No 8
Boston, MA—Rociletinib, a specially engineered third-generation
EGFR
inhibitor, is accumulating an impressive track record in early studies of non–small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the
T790M
mutation, a heretofore patient population with unmet needs.
T790M
, the most common mutation associated with resistance to first-line
EGFR
-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs.
Read Article
Molecular Signature for Neuroendocrine Prostate Cancer Represents Progress
By
Alice Goodman
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
September 2015, Vol 6, No 8
Boston, MA—Researchers have defined an 81-feature molecular signature to identify neuroendocrine prostate cancer (NEPC), an aggressive and rapidly progressing entity that is increasingly being recognized in patients with advanced disease and signals poor overall survival. The signature, derived from genomic, transcription, and methylation analysis, relies heavily on epigenetic alterations.
Read Article
Transforming Medicine: TMed Will Match People with Life-Threatening Illnesses to Best Treatments, in Real Time
By
Robert Goldberg, PhD
Personalized Medicine
September 2015, Vol 6, No 8
TMed will improve the selection of treatments by adding back and analyzing all the relevant data about the variability of response and the multiplicity of causes…from thousands, if not millions, of patients.
Read Article
Oncology Pipeline Full, and Not Just with Immunotherapies
By
Wayne Kuznar
Emerging Therapies
,
Personalized Medicine
September 2015, Vol 6, No 8
Clinicians will soon have more targeted therapies at their disposal, including drugs with novel mechanisms of action.
Read Article
Personalized Medicine Affordability Lies in Enhanced Predictors of Response to Therapy
By
Wayne Kuznar
Personalized Medicine
August 2015, Vol 6, No 7
Washington, DC—Personalized medicine is the best way to take advantage of innovation in therapy, but the method in which it is paid for must be addressed to fully realize its potential, said Michael Kolodziej, MD, National Medical Director, Oncology Solutions, Aetna, at the Fifth Annual Conference of the Association for Value-Based Cancer Care.
Read Article
Combination of PARP and PI3K Inhibitors Share a Genomic Landscape in Breast and Ovarian Cancers
By
Phoebe Starr
Personalized Medicine
August 2015, Vol 6, No 7
Philadelphia, PA—Now that a number of targeted therapies are available for the treatment of cancer, one of the big questions is how to best combine them, especially for patients with few other good treatment options.
Read Article
Cell Surface Amino Acid Potential as Prostate Cancer Biomarker
By
Wayne Kuznar
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
August 2015, Vol 6, No 7
New Orleans, LA—Prostate cancer may soon have a new biomarker. The cell surface amino acid glypican-1 (GPC-1) was shown in a pilot study to have specificity of 70% for prostate cancer with a sensitivity of >30%, said Jonathan Henderson, MD, a urologist at Regional Urology in Shreveport, LA, at the 2015 American Urological Association meeting.
Read Article
Page 18 of 35
15
16
17
18
19
20
21
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma